Category Archives: Reagents

Their improved detection limits also come at a significant cost in terms of time, workflow and equipment overhead that renders them ill-suited to application at the point of care. we find that, even though multistep amplification of an ELISA prospects to a lower detection limits, the medical level of Rabbit Polyclonal to PDZD2 sensitivity of ELISAs, E-DNA detectors and lateral-flow dipsticks are indistinguishable across our test set. It thus appears that, by merging the quantitation and multiplexing of ELISAs with the convenience and rate of dipsticks, E-DNA scaffold detectors could significantly improve on current serological practice. more sensitive (i.e., can detect at lower titers), this does not improve their medical overall performance for our test set. Their improved detection limits also come at a significant cost in terms of time, workflow and products overhead that renders them ill-suited to software at the point of care. Given the value of reducing…

Read more

In the modern era of rituximab-based therapy as the first-line treatment, the prognoses of patients who require salvage therapy are poor and most will eventually succumb to their disease. this molecular era of disease definition will be the identification of combinations of novel brokers that target the oncogenic drivers of these subsets. Well-conducted clinical trials, with translational molecular investigations, will be essential to achieve the goal of precision medicine and expand the number of patients with DLBCL who achieve a cure. Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma (NHL) throughout the world, comprising 30C35% of all NHLs.1 DLBCL is biologically aggressive, but can be cured in 50% of cases, even in advanced stages.2 However, up to one-third of patients have refractory disease or relapse after treatment.3 The standard salvage treatment for patients with relapsed or refractory DLBCL that remains sensitive to chemotherapy is autologous…

Read more

2/2